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ABSTRACT
To investigate the efficacy and safety of haploidentical (from family member donors) hematopoietic stem cell
transplantation (HSCT) for children. 42 children under 14 yrs old with hematological malignancies underwent
haploidentical HSCT. Outcomes were analyzed. Thirty-three children were classified as high-risk candidates.
Of 42 patient/donor pairs, 4 (9.5%) were mismatched in 2 HLA loci, 15 (35.7%) in 3 loci, and 23 (54.8%) in 4
loci. Follow-ups were performed for a median of 1110 (449-1959) days after transplantation. All patients
achieved stable engraftments. The cumulative incidence of acute graft-versus-host disease (aGVHD) of grade
2-4 was 57.2%, and that of grade 3-4 was 13.8%. The cumulative incidence of chronic graft-versus-host disease
(cGVHD)was 56.7% for total and 29.5% for extensive. Twenty-seven patients survived with a 3-yr probability of
leukemia-free survival (LFS), 57.3±8%, 18 of them were in the high-risk group. Fifteen patients died, 4 from in-
fection, 7 from relapse of leukemia, 2 from heart failure, one from severe aGVHD, and one from lymphoproli-
ferative disorders. The results encourage extending haploidentical HSCTwithoutT cell depletion treatments to
children with an indication for transplantation.
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drenINTRODUCTION
Despite recent advances in the diagnosis and treat-
ment of childhood hematological malignancies, there
are several subgroups of children that are at high risk
of failing current chemotherapy regimens and require
allogeneic hematopoietic stem cell transplantation
(HSCT) to cure their disease [1,2]. The first choice of
a donor for allogeneic HSCT is an HLA-identical sib-
ling. However, this is not possible for patients who have
no siblings. The alternatives are an unrelated HLA-
matched donor, umbilical cord blood, or a family mem-
ber that serves as an HLA haploidentical donor. The
unsuccessful or time-consuming donor search process
limits the application of unrelated donors for HSCT.
Although cord blood transplantation (CBT) is more
successful for children than for adults, its outcome is
limited by incomplete hematopoietic and immunereconstitution [3,4]. Recently, we reported a novel
method for haploidentical/mismatched HSCT from
family members without in vitro T cell depletion,
which showed survival, relapse, and graft-versus-host
disease (GVHD) outcomes comparable to those of
transplantation from identical siblings [5,6]. In this
study, we report the results of 42 children under 14
yrs old that received HSCT from haploidentical family
donors within 5 consecutive yrs. The toxicity and effi-
cacy of this transplantation method for children were
investigated.
MATERIALS AND METHODS
Patient Eligibility
Forty-two children under 14 (3-14) yrs old with
hematological disorders underwent haploidentical
HSCT between January 2002 and April 2006 at469
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short-term results of 22 patients were reported in
2006 and subsequent progress was followed up in
this study. None of the patients had HLA-identical
related or unrelated donors, or a source of stem cells
from umbilical cord blood. Twenty-four patients had
acute lymphoblastic leukemia (ALL), twelve patients
had acute myeloid leukemia (AML), and 6 patients
had chronic myelogenous leukemia (CML) before
HSCT. Twenty-nine children with acute leukemia
presented with clinical and biological features that in-
dicated a very high risk of relapse with conventional
chemotherapy. Patients with CML were enrolled be-
cause allogeneic HSCT was the first-line therapy rec-
ommended in China for CML patients who were
under 20 yrs old. Two patients with AML and 5 pa-
tients with ALL in the first and second remissions
(CR1 and CR2, respectively) were enrolled based on
fervent requests from their parents. All the children
were treated with one protocol as described below.
The Institutional Review Board of Peking University
approved this study, and all patients’ guardians and
donors signed consent forms for transplantation and
stem cell collection.
Donor and Stem Cell Harvesting
For eligibility, HSCT recipients had to have allele
types HLA-A, HLA-B, HLA-C, or HLA-DRB1. Low-
resolution DNA techniques were used for HLA typing
of the A and B loci. High-resolution techniques were
used to define class II antigens.
Donors were primed with granulocyte-colony
stimulating factor (G-CSF, Filgrastim, Kirin, Japan;
5 mg/kg per day) injected subcutaneously for 5 consec-
utive days. The target mononuclear cell count (MNC)
was 4-6108 cells/kg recipient weight. On the fourth
day, bone marrow cells were harvested. On the fifth
day, peripheral blood stem cells (PBSC) were collected
with a COBE Blood Cell Separator (Spectra LRS,
COBE BCT, Inc., Lakewood, Colorado, USA) from
a total blood volume of 10L. Forty patients received
G-CSF-primed bone marrow combined with PBSC
at transplantation; one patient received the G-CSF-
primed bone marrow; and the other patient received
PBSC. Surface markers of the cells in the grafts were
determined by 2- or 3-color staining using monoclonal
antibodies specific for CD341, CD31, CD41, and
CD81 cells, essentially as described by Huang et al [7].
Conditioning Regimen and GVHD Prophylaxis and
Therapy
Recipient patients underwent conditioning for 10
days before transplantation; the day of transplantation
was designated day 0. The conditioning regimen con-
sisted of arabinoside (Ara-C, 4 g/m2/d, i.v.) given on
days –10 and –9; busulfan (Bu, 12 mg/kg, p.o. in 12
doses) given on days –8, –7, and –6; cyclophosphamide(Cy, 1.8 g/m2/d, i.v.) given on days –5 and –4; Simus-
tine (Me-CCNU, 250 mg/kg, i.v.) given on day –3; and
antihuman thymocyte immunoglobulin (ATG, 2.5mg/
kg/d of the Sangstat product, i.v.) given on days –5
through –2. All transplant recipients received cyclospor-
ine A (CsA), mycophenolate mofetil (MMF), and short-
term methotrexate (MTX) for GVHD prophylaxis.
The diagnosis and grading of GVHD was done ac-
cording to published criteria [8]. Supportive care was
given as described previously [6]. DNA fingerprinting
of short tandem repeats was used for confirmation of
engraftment and determination of chimerism. Chro-
mosomal fluorescent in situ hybridization (FISH)
was also used to detect chimerism in patients with a do-
nor of a mismatched gender. Acute GVHD (aGVHD)
of grade 2 or higher was treated with methylpredniso-
lone (0.5-1 mg/kg per day). GVHD manifested on the
skin was treated with MTX [9]. When there was inad-
equate or no response to primary therapy, tacrolimus
replaced cyclosporine A or anti-Tac monoclonal anti-
body (Daclizumab; Roche, Basel, Switzerland) was
administered at 1mg/kg i.v. on days 1, 4, 8, and then
at 7-day intervals for a total of 5 to 6 doses. The
first-line therapy for chronic GVHD (cGVHD) was
cyclosporine A combined with prednisone (0.5-1 mg/
kg per day). Tacrolimus and azathioprine were used
in refractory cases. Penicillamine was used in combina-
tion with medications listed above for patients with
generalized skin involvement.
Definition
The severity of acute and chronic GVHD were di-
agnosed with the standard criteria [8]. The date of neu-
trophil recovery was defined as the first day of 3
consecutive days that an absolute neutrophil count of
0.5109/L was achieved. The date of platelet engraft-
ment was defined as the first day of 7 continuous days
that an absolute platelet count of 20109/L was
achieved without the support of transfusion. At day
130, the disease response and chimerism were as-
sessed in peripheral blood and bone marrow. Relapse
was defined as a hematological recurrence of the pri-
mary disease. Death from leukemia was defined as
death with refractory disease after transplantation, or
as death from any cause following relapse after trans-
plantation. Transplantation-related mortality (TRM)
was defined as death during continuous post-trans-
plantation remission.
Patients were stratified into standard-risk and
high-risk groups according to their remission state
before transplantation. High-risk candidates for hap-
loidentical HSCT included patients with acute leuke-
mia (AL) in CR1 and in CR2 with a cytogenetic marker
of ‘‘poor-risk’’, such as the Philadelphia chromosome;
those in complete remission after CR 3; those in non-
remission or in a relapse state before transplantation;
and those with CML beyond the first chronic phase
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dard-risk group.
Supportive Care and Follow-Up
HSCT recipients were attended in isolation
rooms with laminar airflow systems. To prevent in-
fections of pneumocystis carinii, herpes simplex and
varicella-zoster virus (VZV), and Candida albican, pa-
tients were given prophylactic doses of trimethoprim/
sulfametho- xazole (1-2g/d, p.o., from day –10 to day
130, and 2 days/wk up to day 90), acyclovir (0.4-
0.8g/d, p.o. from day 11 to 1 yr), and fluconazole
(50-100mg/d, p.o. from day –10 to myloid recovery),
respectively. To prevent cytomegalovirus (CMV) re-
activation, patients were given ganciclovir (5mg/kg,
i.v. bid.) from day –9 to –2. For treatment of pneumo-
cystis carinii, trimethoprim/sulfamethoxazole was ad-
ministered 4-6g/d, p.o. for 2-3 wks. Children with
a history of fungal infection were given itraconazole
for prophylaxis from day –10 up to myloid recovery.
For treatment of empiric and proven invasive fungal
infections, itraconazole, caspofungin, or emphotericin
B / Amphotec were given. Antifungal agents were
used for 2-3 wks for empiric therapy of fever and
for 3-4 mos for pneumonia with computer tomogra-
phy (CT) findings of infiltration and other proven in-
fections. CMV-DNA levels were determined twice
a week before day 190; after day 190, in case of
extensive cGVHD, blood was examined for pp65
antigenemia with PCR. When viremia was detected
twice, preemptive therapy was started with ganciclo-
vir, which was used for 4 to 6 wks since negative
detection of antigenemia after the therapy. Refractory
CMV antigenemia that was continuously positive
with preemptive therapy, and CMV disease were
treated with forscarnet (90-120mg/d, i.v.) and immu-
noglobulin (40mg/kg7 days, i.v.) combined with
ganciclovir. The course of therapy for proven CMV
disease was 6-8 wks. All children received piperacillin
alone or combined with amikacin for prophylaxis of
bacterial infections from day –10 to myloid recovery.
The first line antibiotics for empiric therapy of fever
during neutropenia were cefepime, meropenem, or
imipenem and sodium cilastatin. If fever was not con-
trolled and microbiological cultures were negative
after 3-5 days of the first line therapy, vancomycin
or teicolanin was added.
Blood products were infused into patients that had
hematocrit levels\25% and/or platelet counts\20 
109/L. All blood products were irradiated prior to use.
During hospitalization, clinical status, adverse
events, hematological parameters, and clinical bio-
chemical parameters were monitored daily. After dis-
charge from the hospital, patients were examined in
the outpatient clinic once to twice per wk up to day
100 and at gradually longer intervals thereafter.
Toxicities were graded according to WHO criteria.Statistics
The primary endpoint of the study was the over-
all survival (OS) rate at 3 yrs from transplantation.
Secondary endpoints included leukemia-free survival
(LFS, defined as survival in continuous complete re-
mission after transplantation), non-relapse mortality,
incidence of relapse, and incidence and severity of
acute and chronic GVHD. The day of stem cell
transfusion was counted as day 0, and all intervals
were calculated based on this date.
Patients were evaluated for aGVHD after engraft-
ment, and for cGVHD starting 100 days after HSCT.
Time to acute or chronic GVHD, relapse, survival,
and LFS were measured from the date of HSCT
(day 0). The risk factors calculated for univariate anal-
ysis included: age and gender of patients and donors;
relation of the patients and donors; time from diagno-
sis to transplantation; HLA disparity; diagnosis and re-
mission status before transplantation; cell subsets
infused in the graft; time of myeloid and platelet en-
graftment; and the incidence of aGVHD, cGVHD,
and infections. The Cox-regression model was not
built due to the limited number of cases. The date of
the last follow-up for all surviving patients was No-
vember 1, 2007. All reported P values were based on
two-sided hypothesis tests. Alpha was set at 0.05. Nu-
meric variables were analyzed as categories consider-
ing their value below or above the median of the
entire cohort, as indicated in the Results section. Acute
and chronic GVHD were analyzed as time-dependent
variables. OS and LFS were estimated using the Ka-
plan-Meier method. The SPSS-13.0 software package
was used for data analysis.
RESULTS
Characteristics of Patients and Engraftment
Twenty-eight donors were mothers and 12 donors
were fathers of the patients. The other 2 donors were an
uncle and a brother; both were haploidentical accord-
ing to the familial spectrum of genetics analysis. All
patients were mismatched at the allele level for HLA-
A, HLA-B, HLA-C, and HLA-DRB1. Twenty-three
(54.8%) patients were mismatched in 4 loci, 15
(35.7%) patients were mismatched in 3 loci, and 4
(9.5%) in 2 loci. The median age of the donors was
36 (17-43) yrs old. The patients were followed up until
November1, 2007 with a median of 1110 (449-1959)
days after transplantation. According to the risk group
definitions mentioned above, 2 patients with AML, 5
patients with ALL, and 2 patients with CML were
stratified into a standard-risk group and 10 AML, 19
ALL, and 4 CML were stratified into a high-risk group.
The characteristics of patients and donors are de-
scribed in Table 1.
The median numbers of MNC infused at trans-
plantation were 8.4 (1.1-15.4) 108/kg. The cell
472 D. Liu et al.subsets infused are listed in Table 2. All patients
achieved stable engraftment and whole donor chime-
rism as detected by DNA fingerprinting of short tan-
dem repeat and chromosomal FISH. The median
times of myeloid and platelet recovery were 14 (9-22)
days and 22 (8-90) days after transplantation, respec-
tively. There was no significant association between
the extent of HLA disparity and the time of myeloid
or platelet recovery (Table 3).
Graft-Versus-Host Disease and Opportunistic
Infections
Thirty-one patients developed aGVHD, with
grade 1 in 11 patients, grade 2 in 16 patients, and grade
4 in 4 patients. Acute GVHD grade 2 occurred in 2 of 4
patients with HLA mismatched in 2 loci, 4 of 15 pa-
Table 1. Characteristcs of children and donors for haploidentical HSCT
Cases %
Age at transplantation (yrs)
.1-5 3 7.1
.5-10 12 28.6
.10#14 27 64.3
Disease and status Total/high-risk %
AML 12 28.7
CR1/CR2 7/5
$CR3 4/4
Non-remission 1/1
ALL 24 57.4
CR1/CR2 15/10
$CR3 5/5
Non-remission 3/3
Ph1* 1/1
CML 6 14.9
CP1 2/0
AP 3/3
BC 1/1
Median time from diagnosis
to transplantation (range)
289(77-1825) days
Year of transplantation
2002-2003 13 30.9
2004 18 42.9
2005-2006.02 11 26.2
Donor-recipient sex match
Female-male 15 35.7
Female- female 13 31.0
male-male 9 21.4
male- female 5 11.9
Donor-recipient relationship
Mother-child 28 66.7
Father-child 12 28.5
Uncle-nephew 1 2.4
Siblings 1 2.4
Blood types of donor
to recipient
Matched 26 61.9
Major mismatched 4 9.5
Minor mismatched 11 26.2
Major and minor 1 2.4
HSCT indicates hematopoietic stem cell transplantation; ALL,
acute lymphoblastic leukemia; AML, acute myelogenous leuke-
mia; CML, chronic myelogenous leukemia.tients mismatched in 3 loci and 10 of 23 patients
mismatched in 4 loci. Acute GVHD grade 4 was diag-
nosed in 2 patients with HLA mismatched in 3 loci,
and in 2 patients mismatched in 4 loci, at days 13,
21, 21, and 29 after transplantation, respectively. Ad-
verse outcomes were found to be unassociated with
the extent of mismatched HLA-loci. The cumulative
incidence of aGVHD was compared among different
HLA disparities as shown in Figures 1a and 1b. The
cumulative incidence of aGVHD grade 2-4 was
57.2% (Figure 1a), and that of aGVHD grade 3-4
was 13.8% (Figure 1b). The target organs of aGVHD
grade 4 were skin, gastrointestinal tract, and liver. Of
the 4 patients that developed aGVHD grade 4, one
died and the remaining 3 recovered. However, one pa-
tient died of subsequent pneumonia 1.5 yrs after trans-
plantation. One of the surviving 2 patients remained
free of GVHD through the last follow-up of 634
days after transplantation, and the other one developed
limited cGVHD at 484 days after transplantation and
recovered 2 mos later.
Factors that might influence the incidence of
GVHD grade 3-4 were analyzed in a univariate analy-
sis that included age and gender of the patients and do-
nors, number of MNC, CD31, CD41,CD81, and
CD341 cells infused at transplantation, diagnosis
and stage of disease before transplantation, and HLA
disparity. None of the factors was found to be signifi-
cantly associated with the incidence of aGVHD grade
3-4.
Thirty-seven patients that survived longer than
100 days after transplantation were evaluated for
cGVHD. Of 17 patients who had no cGVHD, 12 sur-
vived without relapse. Of 11 patients that developed
limited cGVHD, 8 survived. The limited cGVHD in-
volved skin in 6 patients and hepatic function in 2
patients; these were controlled with treatment for
a median of 2 mos. Of 9 patients who developed
Table 2. Cell subsets infused at haploidentical HSCT for children
Cell subsets median range
MNC (108/kg) 8.35 1.10-15.35
MNC in BM (108/kg) 4.75 0.31-11.44
MNC in PB (108/kg) 3.98 0.79-15.35
CD341 (106/kg) 2.92 0.76-8.15
CD341 in BM* (106/kg) 1.65 0.23-6.06
CD341 in PB* (106/kg) 1.43 0.13-5.6
CD31 (108/kg) 1.97 0.22-6.38
CD31 in BM* (108/kg) 0.45 0.01-1.95
CD31 in PB* (108/kg) 1.67 0.09-6.38
CD41 (108/kg) 1.13 0.04-5.23
CD41 in BM* (108/kg) 0.27 0.03-1.19
CD41 in PB* (108/kg) 0.94 0.05-5.23
CD81 (108/kg) 0.84 0.04-2.77
CD81 in BM* (108/kg) 0.19 0.03-1.15
CD81 in PB* (108/kg) 0.71 0.03-2.73
MNC indicates mononeuclear cells; BM, bone marrow; PB, periph-
eral blood.
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Mismatched loci (case)
Patients achieving neutrophil
recovery at day 30 (case)
Patients achieving platelet
recovery at day 30 (case)
Patients achieving platelet
recovery at day 60 (case)
Two-loci, n523 23 17 22
Three-loci, n515 15 13 15
Four-loci, n54 4 2 4extensive cGVHD, 7 survived. The extensive cGVHD
included generalized skin and eye involvement in 3 pa-
tients, and involvement of skin, eye, and oral mucosa in
4 patients. The cumulative incidence of cGVHD was
56.7%, and that of extensive cGVHD was 29.5%
(Figure 2). The development of cGVHD and its exten-
sive type was not associated with the age or gender of
the patients or donors, numbers of MNC, CD31,
CD41, CD81, or CD341 cells infused at transplan-
tation, the extent of HLA disparity, or the stage of
disease before transplantation.
Nineteen opportunistic infections were observed
within the follow-up time. The causes of opportunistic
infection were pneumonia (6 cases), VZV (3 cases),
bacteremia (Klebsiella Pneumoniae and Staphylococ-
cus Aureus), infection in the gastrointestinal tract
(CMV), and infection in the central nervous system
(Aspergillosis). The causes of pneumonia were CMV
in one case, fungi in one case (Aspergillosis), bacteria
in one case (Staphylococcus Aureus), and idiopathic
interstitial pneumonia in 3 cases. CMV antigenemia
was detected in 18 patients; however, only one case
of interstitial pneumonia (IP) was associated with
CMV. Epstein-Barr virus (EBV) antigenemia was
detected in 2 children and one of these died of EBV-
associated lymphoproliferative disorder.
Hemorrhagic cystitis developed in 6 children at 25
to 160 (median 40) days after transplantation, and
lasted for 2 to 6 (median 3.5) wks. Seizures occurred
in 3 cases within 2 mos after transplantation with no
abnormalities found in magnetic resonance imaging
of brain or cerebral electric examinations. However,
at the time of occurrence, serum CsA concentrations
were at a minimum of 132ng/ml and 287ng/ml (nor-
mal range: 150-250 ng.ml), respectively. After the
discontinuance of intravenous CsA, the seizures were
resolved.
Table 4. Recovery of T cell subsets in the blood in children receiving
haploidentical HSCT
Median of T-cell
counts/Months
after
transplantation
Before
Conditioning
(n55)
1M
(n55)
3M
(n55)
6M
(n55)
12M
(n53)
CD31 (cells/ml) 302.23 89.05 492.12 690.02 1264.66
CD41 (cells/ml) 146.24 40.18 149.78 170.94 382.00
CD81 (cells/ml) 127.72 58.36 310.24 588.61 1066.01Five children without GVHD were followed up for
T cell subset recovery in the blood. At 3 mos after
transplantation the median CD41 and CD81 cell
counts were 149.78 and 310.24 cells/ml, respectively.
At 1 year, data were only obtained in 3 children and
CD41 and CD81 cell counts were 382.00 and
1066.01 cells/ml, respectively. Of the 5 children with-
out GVHD, 4 children survived free of relapse without
any complications for 332, 788, 802, and 833 days after
transplantation, and one child died of heart failure.
Figure 1. (A) Cumulative incidence of acute GVHD grade 2-4 with
HLA disparity after haploidentical HCT for children. Among HLA-
A, B, DRB1, 4 patients with 1 mismatched locus, 15 patients with 2
mismatched loci and 23 with 3 mismatched loci. Tick marks indicate
censored patients. (B) Cumulative incidence of acute GVHD grade 3
and 4 with HLA disparity after haploidentical HCT for children.
Tick marks indicate censored patients.
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Up to November 1, 2007, 27 patients survived.
Twenty-five were free of leukemia: 10 patients with
ALL survived through a median of 539 (40-1478)
days, 10 with AML survived through a median of 663
(119-1629) days, and 5 with CML survived through
a median of 780 (598-1337) days. Eighteen of the 25
patients were classified as high-risk candidates before
transplantation with a 52.269.5% probability of
LFS. Seven out of 9 patients in the standard-risk group
survived free of leukemia. The 3-yr probability of LFS
for all patients was 57.368% (Fig 3a). The quality of
life of the survivors was evaluated with the Lansky
Play-performance scale. Five patients that scored
70% were under treatment for extensive GVHD. Of
3 patients that scored 80%, 2 developed cGVHD.
Twelve patients scored 90% and 7 patients scored
100%.
Fifteen patients died. Seven patients died from re-
lapse of leukemia at a median of 476 (160-706) days af-
ter HSCT. Four patients died from infection: 2 from
pneumonia on day 300 and 463, one from cytomegalo-
virus interstitial pneumonia on day 68, and one from
cerebral fungal infection on day 170. Two patients
died from heart failure on days 40 and 184; both had
received chemotherapy before transplantation for 2
and 4 yrs, respectively. One died from severe aGVHD
on day 67. Another died from EBV-associated lym-
phoproliferative disorder on day 55. The transplanta-
tion related mortality was 9.564.5% at 100 days and
20.466.5% at 1 yr after transplantation.
All 9 of the patients who relapsed after HSCT were
diagnosed with ALL before transplantation, and 5
were from the high-risk group. The probability of
relapse for high-risk patients was 37610.2% at 2 yrs
Figure 2.Cumulative incidence of chronic GVHD after haploident-
ical stem cell transplantation for children. Twenty of thirty-seven pa-
tients that survived longer than 100 days after transplantation
developed chronic GVHD, of whom nine had extensive type. Tick
marks indicate censored patients.after transplantation (Figure 3b). 2 patients experi-
enced hematological relapses of leukemia at 180 days
and 120 days after transplantation; they received che-
motherapy followed by donor lymphocyte infusions
(DLI). They achieved complete remission and 100%
donor chimerism 4 wks after DLI and were free of dis-
ease recurrence at follow-ups 1185 days and 1024 days
after transplantation.
The univariate analysis identified several clinical
factors that were associated with relapse and LFS after
transplantation, including: age of the patients (P5.567
and.678), gender of the patients (P5.672 and.383),
gender pair of the patients and donors (P5.685 and
Figure 3. (A) Probability of leukemia-free survival in different risk
groups after haploidentical HCT for children. Twenty-five of
forty-two patients survived without recurrence of disease. Eighteen
patients were classified into high-risk group and twenty-four patients
in standard-risk group. Tick marks indicate censored people. (B)
Probability of relapse in different risk groups after haploidentical
HCT for children. Nine patients relapsed after transplantation and
five of them were from high-risk group. Tick marks indicate cen-
sored people.
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(TNC: P5.536 and.827; CD341: P5.681 and.932;
CD31: P5.278 and.449), risk stratification of disease
before transplantation (P5.445 and.251), time between
diagnosis and transplantation (P5.339 and.600), time
of myeloid recovery (P5.310 and .779), time of platelet
recovery (P5 .812 and .640), HLA disparity (P5
.068 and .427), occurrence of aGVHD grade 2-4
(P5 .832 and .629), occurrence of extensive cGVHD
(P5.080 and .631), and occurrence of opportunistic in-
fections (P5.238 and .860). In addition, a diagnosis of
ALL was associated with a lower probability of LFS
(Figure 4a, P5.008) and a higher probability of relapse
Figure 4. (A) Probability of leukemia-free survival with different di-
agnosis after haploidentical HCT for children. Ten of twenty-four
patients survived without recurrence of disease. Fifteen of eighteen
patients with diagnosis of AML and CML survived without relapse.
Tick marks indicate censored people. (B) Probability of relapse with
different diagnosis after haploidentical HCT for children. Nine pa-
tients relapsed after transplantation were all diagnosed as ALL be-
fore transplantation. No patients with AML or CML relapsed
within the follow-up. Tick marks indicate censored people.(Figure 4b, P5.008) after transplantation. The occur-
rence of cGVHD was associated with a lower rate of re-
lapse after transplantation (P5.019) (Figure 5).
Patients with doses of CD341\ 2106 cells/kg and
.2106 cells/kg had 50.2612.7% and 68.969.9%
probabilities of LFS, respectively (P5.352), and no ad-
verse influences were observed on relapses, GVHD, or
opportunistic infections.
DISCUSSION
The prognosis for childhood hematological malig-
nancies has improved dramatically over the past quarter
of a century. A recent comparative study for allogeneic
transplantation in children demonstrated that the 5-yr
LFS rates were 38% after HLA-matched bone marrow
transplants, 60% after HLA-matched CBT, and 33%-
45% after mismatched CBT. However, CBT offered
no advantage in platelet and neutrophil recovery,
occurrence of cGVHD, TRM, or survival compared
with the bone marrow transplantation from identical
siblings [3]. Recently, we described a HLA-mis-
matched/haploidentical T cell replete HSCT (n5171,
149 adults) for treatment of leukemia that achieved re-
sults comparable to transplantation from identical sib-
lings [5,6]. However, to date, in most transplantation
centers HSCT from mismatched family members is
performed only in the context of a primary clinical trial
and has not been recommended for patients with no
identical sibling donors. The current study investigated
the efficacy and toxicity of haploidentical HSCT as
a leukemia treatment for children under 14 yrs old,
most with high-risk hematological malignancies.
Figure 5. Influence of chronic GVHD on replase after haploident-
ical HCT for children. Lower probability of relapse was associated
with occurrence of chronic GVHD, one of seven patients with
chronic GVHD relapsed and eight of twelve patients without
chronic GVHD relapsed. Tick marks indicate censored patients.
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acute grade 3-4 GVHD, 56.7% for cGVHD, and
29.5% for extensive cGVHD in children after haploi-
dentical HSCT. These results were comparable to
those reported in studies that used HLA-identical
and unrelated donors for HSCT [1,10]. The results re-
ported here in children were lower than those reported
previously in adults receiving HLA-mismatched/hap-
loidentical T cell replete HSCT (23.1%, 73.6% and
46.9%, respectively) [6]. Consequently, the quality of
life after haploidentical HSCT for the children was
much better than that of the adults.
Presently, more than 70% of children with newly
diagnosed ALL that were treated with multiagent che-
motherapy with or without radiotherapy survived and
are disease free 5 yrs after treatment [11]. However, pa-
tients that are in CR1 with a high risk of failing current
chemotherapy regimens or relapse within the first year
of diagnosis require alternative treatment strategies
[12]. Treatments with matched related allogeneic
HSCT had previously been restricted to children
who relapsed during or after primary intensive chemo-
therapy. The 5-yr LFS rate was 29% after matched
related allogeneic HSCT for children that had ALL
and an initial bone marrow relapse within 12 mos of
completion of primary therapy [13]. Another study
showed that children with ultra-high-risk features of
ALL (Philadelphia chromosome, induction failure,
age$10yr, and WBC count$200,000/mm3) may ben-
efit from transplantation in CR1, especially patients
with primary induction failure and Philadelphia chro-
mosome; the 5-yr LFS rate was 58.6% for these
patients after HSCT from matched family donors
[14]. In our present study, the 3-yr LFS rate was
52.269.5% for children with high-risk leukemia, in-
cluding patients with acute leukemia in CR1 or CR2
with Philadelphia chromosome, in remission after
CR3, or in a non-remission state. Though in most
transplantation centers unrelated donor or cord blood
transplants were recommended for children with high-
risk ALL who did not have identical sibling donors, the
data in the present study encourage the use of haploi-
dentical family member donors, even for children
with ALL that are in CR1 or CR2, but who have poor
risk features.
Relapse and heart failure were the main causes of
mortality after transplantation. All 9 children in this
study who relapsed after transplantation were diag-
nosed with ALL and were classified as high-risk can-
didates. Two children died of heart failure early after
transplantation; this suggests that it is important to
make timely choices to avoid unnecessarily long
courses of conventional therapy that might result in
irreversible organ injury. The incidence of opportu-
nistic infections observed with our transplantation
regimen was less than that reported with the Perugia
regimen and T cell depleted grafts; this suggeststhat overall post-transplantation T cell reconstitution
is significantly better with our regimen than that re-
ported by Waller et al [15,16]. The limited data of
the present study show that, in the 5 patients without
GVHD or other complications, T cell and T cell sub-
set recovery was at least comparable and possibly
faster than the recovery rate reported previously,
which indicated the potential role of the age of these
patients in immune reconstitution [17-18].
Future research on children with high-risk leuke-
mia might address the following questions: what is
the role of stratifying patients into risk groups, includ-
ing the role of cytogenetic screening, in selecting can-
didates for allogeneic HSCT, especially those in CR1?
What is the optimal timing and appropriate use of hap-
loidentical donor HSCT, given that a matched related
donor is not available?
An evidence-based review published recently eval-
uated the role of HSCT as a therapy for children with
AML. It showed that allogeneic HSCT from identical
sibling donors resulted in superior overall survival and
DFS rates compared to autologous HSCT and chemo-
therapy for children in CR1 or CR2 [19]. In a study by
Alonzo et al., the 8-yr LFS for children with AML-
CR1 was 4765% after allogeneic HSCT with identical
sibling donors (n5373), 4267% after autologous
HSCT (n5217), and 3464% after chemotherapy
alone (n5688) (P5.004) [20]. They recommended
a matched unrelated or other alternative donor should
be used for HSCT in the context of a clinical trial. In
our study, 10 of 12 children with AML (5 children
were in CR1) achieved LFS through 663(119-1629)
days. Though the number of cases was limited, the pri-
mary data demonstrated the safety and efficacy of hap-
loidentical HSCT for children with AML.
CML constitutes 3-5% of all childhood leukemias.
Though the treatment of CML with tyrosine kinase
inhibitor has been proven successful for several years,
allogeneic HSCT is the only proven curative treat-
ment for children with CML. In our study 5 out of 6
children with CML achieved LFS for a median of
780 (598-1337) days. Currently, allogeneic HSCT,
including haploidentical transplantation for children
with no identical donors, is the first line of treatment
planned in our unit after the diagnosis of CML is
established.
The use of family donors with 2 to 3 mismatched
loci is considered a viable approach, despite the
prompt availability of another suitable donor. This
is based on the results observed in the high-risk
group, where 9 children received haploidentical
HSCT under the fervent request of their parents.
Two children with CML had an indication for haploi-
dentical HSCT due to the lack of identical sibling
donors. Out of the 9 children, 3 died of infection or
GVHD after transplantation. This indicated that chil-
dren with standard-risk leukemia should not be
Haploidentical HSCT without T cell depletion for children with leukemias 477recommended for haploidentical HSCT. Though the
results of this study should be interpreted cautiously
due to the small number of patients, the primary re-
sults from children with high-risk leukemia suggested
the feasibility of haploidentical HSCT in cases where
no HLA identical donors are available. Although pro-
spective, randomized studies are needed to address
the more complex issues, the results described here
support the use of haploidentical family members as
donors. This strategy is likely to be most appropriate
for patients who have no siblings.
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